{"id":1171,"date":"2020-04-23T13:33:04","date_gmt":"2020-04-23T13:33:04","guid":{"rendered":"https:\/\/areyoucovidmune.com\/covidmune\/?page_id=1171"},"modified":"2020-04-23T13:55:25","modified_gmt":"2020-04-23T13:55:25","slug":"pharmacological-inhibitors-of-the-nlrp3-inflammasome","status":"publish","type":"page","link":"https:\/\/areyoucovidmune.com\/covidmune\/pharmacological-inhibitors-of-the-nlrp3-inflammasome\/","title":{"rendered":"Pharmacological Inhibitors of the NLRP3 Inflammasome"},"content":{"rendered":"

[et_pb_section fb_built=”1″ fullwidth=”on” _builder_version=”3.19.3″ background_image=”https:\/\/areyoucovidmune.com\/covidmune\/wp-content\/uploads\/2019\/11\/shutterstock_112250879.jpg” custom_padding=”0px|0px|0|0px|false|false”][et_pb_fullwidth_header title=”Are You CovidMune?™” text_orientation=”center” _builder_version=”3.19.3″ title_level=”h2″ title_font=”|800|||on|||#e02b20|” title_text_color=”#ffffff” content_font=”|700|||||||” content_text_color=”#000000″ subhead_font=”||||on|||#e02b20|” subhead_text_color=”#ffffff” subhead_font_size=”30px” background_image=”https:\/\/areyoucovidmune.com\/covidmune\/wp-content\/uploads\/2020\/04\/covid-19-dna.jpg” custom_button_one=”on” button_one_text_color=”#ffffff” button_one_border_color=”#e02b20″ button_one_font=”|600|||||||” box_shadow_style_button_one=”preset2″][\/et_pb_fullwidth_header][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.19.3″ custom_padding=”7px|0px|0|0px|false|false”][et_pb_row _builder_version=”3.19.3″ custom_padding=”27px|0px|0|0px|false|false”][et_pb_column type=”4_4″ _builder_version=”3.19.3″ parallax=”off” parallax_method=”on”][et_pb_text _builder_version=”3.19.3″]<\/p>\n

Pharmacological Inhibitors of the NLRP3 Inflammasome<\/span><\/u><\/b><\/span><\/h4>\n

<\/a><\/p>\n

\n
\n
\n
Front Immunol<\/a><\/span>. 2019; 10: 2538. <\/span><\/div>\n
Published online 2019 Oct 25. <\/span>doi:\u00a010.3389\/fimmu.2019.02538<\/a><\/span><\/div>\n<\/div>\n<\/div>\n
\n
\n
PMCID: <\/span>PMC6842943<\/span><\/div>\n
PMID: 31749805<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n
\n
Ayesha Zahid<\/a>,1,<\/sup>2<\/sup> Bofeng Li<\/a>,1,<\/sup>2<\/sup> Arnaud John Kombe Kombe<\/a>,2<\/sup> Tengchuan Jin<\/a>,1,<\/sup>2,<\/sup>3,<\/sup>*<\/sup> and Jinhui Tao<\/a>1,<\/sup>*<\/sup><\/div>\n
\n
Author information<\/a> Article notes<\/a> Copyright and License information<\/a> Disclaimer<\/a><\/div>\n<\/div>\n<\/div>\n

<\/span><\/p>\n

<\/span><\/p>\n

<\/h4>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.3″ custom_padding=”0|0px|0|0px|false|false”][et_pb_column type=”4_4″ _builder_version=”3.19.3″ parallax=”off” parallax_method=”on”][et_pb_text _builder_version=”3.19.3″]<\/p>\n

Abstract<\/h2>\n
\n

Inflammasomes play a crucial role in innate immunity by serving as signaling platforms <\/span>which deal<\/g> with a plethora of pathogenic products and cellular products associated with stress and damage. By far, the <\/span>best studied<\/g> and most characterized inflammasome is NLRP3 inflammasome, which consists of NLRP3 (nucleotide-binding domain leucine-rich repeat (NLR) and pyrin <\/span>domain containing<\/g> receptor 3), ASC (<\/span>apoptosis-associated<\/g> speck-like protein containing a caspase recruitment domain), and procaspase-1. Activation of NLRP3 inflammasome is mediated by highly diverse stimuli. Upon activation, NLRP3 protein recruits the adapter ASC protein, which recruits the procaspase-1 resulting in its cleavage and activation, inducing the maturation, and secretion of inflammatory cytokines and pyroptosis. However, aberrant activation of the NLRP3 inflammasome is implicated in various diseases including diabetes, atherosclerosis, metabolic syndrome, cardiovascular, and neurodegenerative diseases; raising a tremendous clinical interest in exploring the potential inhibitors of NLRP3 inflammasome. Recent investigations have disclosed various inhibitors of the NLRP3 inflammasome pathway which were validated through in vitro\u00a0<\/g><\/em><\/span>studies<\/g> and in vivo<\/em> experiments in animal models of NLRP3-associated disorders. Some of these inhibitors directly target the NLRP3 protein whereas some are aimed at other components and products of the inflammasome. Direct targeting of NLRP3 protein can be a better choice because it can prevent <\/span>off target<\/g> immunosuppressive effects, thus restrain tissue destruction. This paper will review the various pharmacological inhibitors of the NLRP3 inflammasome and will also discuss their mechanism of action.<\/span><\/p>\n<\/div>\n

Keywords: <\/strong>NLRP3 inflammasome, inhibitors, MCC950, drug screening, IL-1\u03b2<\/span><\/span><\/div>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.3″ custom_padding=”18px|0px|27px|0px|false|false”][et_pb_column type=”4_4″ _builder_version=”3.19.3″ parallax=”off” parallax_method=”on”][et_pb_text _builder_version=”3.19.3″]<\/p>\n

Introduction<\/h2>\n

In mammals, the immune system relies on innate immunity and adaptive immunity to protect the host from any external or internal danger (1<\/a>). The innate immune response utilizes pattern-recognition receptors (PRRs) to sense endogenous or exogenous pathogens (2<\/a>). A newly identified PRR, which was reported in detail for the first time in 2002, is the inflammasome. It is a high molecular weight protein complex <\/span>which elicits<\/g> the activation of inflammatory caspases and processing of pro-interleukin-1\u03b2 (pro-IL-1\u03b2). Inflammasomes are of vital importance in innate immunity because they serve as signaling platforms <\/span>which are<\/g> capable of dealing with a plethora of pathogenic products and cellular products associated with stress and damage (3<\/a>, 4<\/a>). At present, there are five inflammasomes which are clearly identified, including nucleotide-binding domain leucine-rich repeat (NLR) and pyrin <\/span>domain containing<\/g> receptor 1 (NLRP1), NLRP3, and NLR and caspase recruitment <\/span>domain containing<\/g> receptor 4 (NLRC4) and the AIM2-like receptors (ALR) family including absent in melanoma 2 (AIM2) (5<\/a>, 6<\/a>). This review will describe NLRP3 inflammasome and some reported pharmacological inhibitors targeting this most important inflammasome complex.<\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.3″ custom_padding=”0|0px|27px|0px|false|false”][et_pb_column type=”4_4″ _builder_version=”3.19.3″ parallax=”off” parallax_method=”on”][et_pb_text _builder_version=”3.19.3″]<\/p>\n

NLRP3 Inflammasome<\/h2>\n

NLRP3 inflammasome is the <\/span>best characterized<\/g> inflammasome at present, named after the NLRP3 protein in the complex which belongs to the NLR family and is also termed as NALP3, CIASI or pyrin domain-containing protein 3 (7<\/a>). Besides NLRP3 protein, the adapter protein apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) and procaspase-1 are also part of this inflammasome (8<\/a>, 9<\/a>). NLRP3 is a 115 kDa cytosolic protein expressed in monocytes, neutrophils, dendritic cells, lymphocytes, osteoblasts, and epithelial cells (10<\/a>). It contains three domains which are: a leucine-rich repeat (LRR) at the C-terminal, a central nucleotide-binding <\/span>and<\/g> oligomerization domain NACHT which possesses ATPase activity, and a pyrin domain (PYD) at the N-terminal which recruits ASC (11<\/a>). The danger signal is sensed by the LRR domain which leads to the oligomerization of NLRP3 monomers through their NACHT domains. This is followed by the interaction between the PYD domains of NLRP3 and ASC. Finally, procaspase-1 is recruited into the complex through its CARD domain by ASC which acts as an adaptor protein (12<\/a>). Recently, Sharif et al. determined the structure of <\/span>recombinant<\/g> complex of <\/span>maltose binding<\/g> protein (MBP)-tagged NLRP3 protein without pyrin domain and mitotic Ser\/Thr kinase NEK7. The <\/span>cryo EM<\/g> map showed an earring shape structure composed of curved LRR and globular NACHT domains. The C-terminal lobe of NEK7 interacts with multiple NLRP3 domains including the LRR, HD2 (helical domain 2), and NBD (nucleotide-binding domain). This structure suggests the possibility that NEK7 joins adjacent NLRP3 subunits into bipartite interactions to bring about the activation of NLRP3 inflammasome (13<\/a>).<\/span><\/p>\n

NLRP3 Inflammasome recognizes a wide range of stimuli which include various protozoans, e.g., Plasmodium<\/em>, ameba, viruses such as adenoviruses, influenza, and Sendai virus, fungi such as Saccharomyces cerevisiae<\/em> and Candida albicans<\/em>, different bacteria such as Listeria monocytogenes, Escherichia coli<\/em>, and Staphylococcus aureus<\/em> (14<\/a>). NLRP3 Inflammasome can also respond to damage-associated endogenous factors such as drusen (15<\/a>), uric acid crystals (16<\/a>), extracellular adenosine triphosphate (ATP) (17<\/a>), \u03b2-amyloid plaques (11<\/a>), and islet amyloid polypeptide (18<\/a>).<\/span><\/p>\n

Activation of <\/span>NLRP3<\/g> inflammasome signaling pathway needs two independent yet parallel steps i.e., priming and activation (19<\/a>\u201321<\/a>). Basal expression of NLRP3 protein and the precursor pro-form of IL-1\u03b2 is very low, therefore a priming step or \u201csignal 1\u201d initiates the transcription of these targets. Priming step is induced by toll-like receptors (TLRs), myeloid differentiation primary response 88 (MyD88) and\/or cytokine receptors, e.g., TNF receptor, which <\/span>recognize<\/g> PAMPs or DAMPs and <\/span>activate<\/g> the transcription of NLRP3 and pro-IL-1\u03b2 (14<\/a>, 22<\/a>, 23<\/a>) as illustrated in Figure 1<\/a>. Recently, many studies have provided strong <\/span>evidences<\/g> that priming step is not limited to transcriptional upregulation, post-translational modifications (PTMs) such as ubiquitination and phosphorylation of NLRP3 protein also play critical roles in NLRP3 inflammasome activation (24<\/a>\u201326<\/a>). The second activation step occurs as the primed cell recognizes another stimulus (usually a DAMP) (27<\/a>, 28<\/a>).<\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.3″][et_pb_column type=”4_4″ _builder_version=”3.19.3″ parallax=”off” parallax_method=”on”][et_pb_image src=”https:\/\/areyoucovidmune.com\/covidmune\/wp-content\/uploads\/2020\/04\/nlrp3-01.jpg” _builder_version=”3.19.3″][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.3″ custom_padding=”0|0px|14px|0px|false|false”][et_pb_column type=”4_4″ _builder_version=”3.19.3″ parallax=”off” parallax_method=”on”][et_pb_text _builder_version=”3.19.3″]<\/p>\n

Figure 1<\/span><\/strong>
Schematic illustration of <\/span>NLRP3<\/g> inflammasome pathway and potential blockade sites of various pharmacological inhibitors. The signal 1 or the priming signal is mediated by pathogenic PAMPs from bacteria or virus, or sterile DAMPs resulting in NF-\u03baB-dependent upregulation of NLRP3 and pro-IL-1\u03b2 expression. The signal 2 or activation signal mediated by numerous PAMP or DAMP stimulation, promotes the NLRP3 oligomerization, and recruitment of ASC and pro-caspase-1, leading to the activation of NLRP3 inflammasome complex. NLRP3 can be activated in response to extracellular ATP and K+ efflux through the ATP-gated P2X7 channel, in response to cathepsin B release from damaged lysosomes or in response to reactive oxygen species (ROS) released from damaged mitochondria. NLRP3 inflammasome activation results in active caspase-1, which cleaves the proforms of IL-1\u03b2 and IL-18 into their mature forms. ASC, <\/span>apoptosis-associated<\/g> speck-like protein containing a C-terminal caspase recruitment domain; ATP, adenosine triphosphate; BHB, \u03b2-Hydroxybutyrate; CARD, caspase recruitment domain; DAMPS, danger or <\/span>damage associated<\/g> molecular patterns; IL, interleukin; LRR, leucine-rich repeat; MNS, methylenedioxy-\u03b2-nitrostyrene; NACHT, central nucleotide-binding and oligomerization; NF-\u03baB, nuclear factor kappa B; Ori, oridonin; P2X7, P2X purinergic receptor 7; PAMPS, <\/span>pathogen<\/g> associated<\/g> molecular patterns; PYD, pyrin domain; ROS, reactive oxygen species; TLR, toll-like receptor; TR, tranilast.<\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.3″ custom_padding=”0|0px|27px|0px|false|false”][et_pb_column type=”4_4″ _builder_version=”3.19.3″ parallax=”off” parallax_method=”on”][et_pb_text _builder_version=”3.19.3″]<\/p>\n

As a result of the second step, caspase-1 is activated and carries out resultant processing and secretion of IL-1\u03b2 and IL-18 (29<\/a>). Various molecular mechanisms to explain the activation of NLRP3 inflammasome have been proposed which include mitochondrial reactive oxygen species (ROS) generation (30<\/a>, 31<\/a>), pore formation and<\/g> potassium (K+<\/sup>) efflux (32<\/a>, 33<\/a>) and lysosomal destabilization and rupture (30<\/a>, 34<\/a>).<\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.3″][et_pb_column type=”4_4″ _builder_version=”3.19.3″ parallax=”off” parallax_method=”on”][et_pb_text _builder_version=”3.19.3″]<\/p>\n

NLRP3 Inflammasome Associated Diseases<\/h2>\n

Anomalous NLRP3 inflammasome activation is linked with the development of many diseases, especially age-associated ailments <\/span>for example<\/g> various metabolic syndromes and metabolic disorders including gout (16<\/a>), atherosclerosis (35<\/a>), Alzheimer’s disease (AD) (11<\/a>), and type II diabetes (T2D) (36<\/a>). Enhanced secretion of IL-1\u03b2 and IL-18 by NLRP3 inflammasome is associated with the progression of atherosclerotic plaque in atherosclerotic patients and animal models (37<\/a>\u201339<\/a>). NLRP3 inflammasome is involved in experimental autoimmune encephalomyelitis (EAE) in animal models and multiple sclerosis (MS) in humans (40<\/a>, 41<\/a>). Inappropriate NLRP3 inflammasome activation is also implicated in Crohn’s disease, inflammatory bowel disease (IBD), and ulcerative colitis (42<\/a>\u201344<\/a>). NLRP3 inflammasome is also linked with various cancers, such as colon cancer, breast cancer, melanoma, hepatitis C virus-associated hepatocellular carcinoma, and gastrointestinal cancers (45<\/a>, 46<\/a>). In addition to NLRP3 activation anomalies, there are also NLRP3 genetic abnormalities collectively termed as cryopyrin-associated periodic syndromes (CAPS). <\/span>Gain<\/g> of function mutations in NLRP3<\/g><\/em> gene <\/span>give<\/g> rise <\/span>CAPS<\/g> disorders, resulting in enhanced IL-1\u03b2 secretion, and other CAPS specific symptoms (47<\/a>).<\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.3″ custom_padding=”0|0px|27px|0px|false|false”][et_pb_column type=”4_4″ _builder_version=”3.19.3″ parallax=”off” parallax_method=”on”][et_pb_text _builder_version=”3.19.3″]<\/p>\n

Pharmacological Inhibition of NLRP3 Inflammasome<\/h2>\n

The association of NLRP3 inflammasome with the plethora of diseases evokes a substantial interest in the scientific community to discover the effective NLRP3 inflammasome inhibitors. By taking advantage of <\/span>complex<\/g> signaling cascade of <\/span>NLRP3<\/g> inflammasome, a diverse range of targets can be used for its inhibition. For example, inhibition of NLRP3 inflammasome activation, suppression of upstream signals, blockade of inflammasome assembly, caspase-1 activation inhibition, blockade of pore-forming protein <\/span>gasdermin<\/g> D (GSDMD) cleavage, and neutralizing the inflammatory cytokines produced by the NLRP3 inflammasome can be targeted for potential inhibition of NLRP3 inflammasome. Different mechanisms can be opted to achieve these outcomes for example inhibition of NLRP3 inflammasome assembly, inhibition of P2X7 receptor, inhibition of K+<\/sup> efflux, and ROS scavengers can be used (48<\/a>\u201351<\/a>). Furthermore, NLRP3-NLRP3 interactions or NLRP3-ASC interactions can be disrupted. Inhibitors can be directed at the ATP-binding domain of NLRP3 resulting in blockade of its ATPase activity (52<\/a>, 53<\/a>). PTMs of NLRP3 protein and other constituents of the NLRP3 inflammasome <\/span>are<\/g> reported as an important step to control its assembly. It can be anticipated that future studies may target the biological components which are involved in these PTMs to inhibit NLRP3 inflammasome. In <\/span>the recent<\/g> years, several inhibitors of <\/span>NLRP3<\/g> inflammasome pathway have been reported. Here, we describe some recent pharmacological inhibitors of <\/span>NLRP3<\/g> inflammasome pathway, their proposed mode of action <\/span>and<\/g> therapeutic potential (Table 1<\/a>). Figure 1<\/a> depicts the proposed sites of action of these inhibitors provided by in vitro<\/em> and in vivo<\/g><\/em><\/span>experimental<\/g> data.<\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.3″ custom_padding=”27px|0px|0|0px|false|false”][et_pb_column type=”4_4″ _builder_version=”3.19.3″ parallax=”off” parallax_method=”on”][et_pb_text _builder_version=”3.19.3″]<\/p>\n

Table 1<\/h3>\n
\n

Potential inhibitors of NLRP3 inflammasome and their targets.<\/span><\/strong><\/p>\n<\/div>\n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Agent<\/strong><\/th>\nTarget(s)<\/strong><\/th>\nPotential mechanism<\/strong><\/th>\nReferences<\/strong><\/th>\n<\/tr>\n<\/thead>\n
Glyburide<\/span><\/td>\nNLRP3 (indirectly)<\/span><\/td>\nInhibits ATP-sensitive K+<\/sup> channels; downstream of P2X7 resulting in inhibition of ASC aggregation<\/span><\/td>\n(48<\/a>, 54<\/a>)<\/td>\n<\/tr>\n
16673-34-0<\/span><\/td>\nNLRP3 (indirectly)<\/span><\/td>\nInduces NLRP3 conformational changes secondary to its activation or binding to ASC<\/span><\/td>\n(55<\/a>, 56<\/a>)<\/td>\n<\/tr>\n
JC124<\/span><\/td>\nNLRP3?<\/span><\/td>\nBlocks the expression of NLRP3, ASC, caspase-1, pro-IL-1\u03b2, TNF\u03b1 and iNOS<\/span><\/td>\n(57<\/a>)<\/td>\n<\/tr>\n
FC11A-2<\/span><\/td>\nNLRP3 (indirectly)<\/span><\/td>\nInterferes with proximity induced autocleavage of pro-caspase-1, suppresses IL-1\u03b2\/18 release<\/span><\/td>\n(58<\/a>)<\/td>\n<\/tr>\n
Parthenolide<\/span><\/td>\nNLRP1, NLRP3 inflammasome, Caspase-1, NF-\u03baB, IKK\u03b2 kinase activity<\/span><\/td>\nAlkylates cysteine residues in caspase-1 and in ATPase domain of <\/span>NLRP3,<\/g> inhibits NLRP3 ATPase activity<\/span><\/td>\n(59<\/a>, 60<\/a>)<\/td>\n<\/tr>\n
VX-740<\/span><\/td>\nCaspase-1<\/span><\/td>\nCovalent modification of the catalytic cysteine residue in the active site of caspase-1 resulting in caspase-1 blocking and resultant cleavage of pro-IL-1\u03b2\/18<\/span><\/td>\n(61<\/a>, 62<\/a>)<\/td>\n<\/tr>\n
VX-765<\/span><\/td>\nCaspase-1<\/span><\/td>\nCovalent modification of the catalytic cysteine residue in the active site of caspase-1 resulting in caspase-1 blocking and resultant cleavage of pro-IL-1\u03b2\/18<\/span><\/td>\n(61<\/a>, 63<\/a>)<\/td>\n<\/tr>\n
Bay 11-7082<\/span><\/td>\nNLRP3, IKK, E2\/3 enzymes, PTPs<\/span><\/td>\nAlkylates the cysteines in the ATPase domain of NLRP3, inhibits NLRP3 ATPase activity<\/span><\/td>\n(59<\/a>, 64<\/a>\u201366<\/a>)<\/td>\n<\/tr>\n
BHB<\/span><\/td>\nNLRP3 (Indirectly)<\/span><\/td>\nInhibits K+<\/sup> efflux resulting in reduced oligomerization of ASC and IL-1\u03b2\/18 release<\/span><\/td>\n(49<\/a>)<\/td>\n<\/tr>\n
MCC950<\/span><\/td>\nNLRP3<\/span><\/td>\nBlocks the ATPase domain of NLRP3 resulting in inhibition of canonical and non-canonical NLRP3 inflammasome activation<\/span><\/td>\n(67<\/a>, 68<\/a>)<\/td>\n<\/tr>\n
MNS<\/span><\/td>\nNLRP3<\/span><\/td>\nInhibits NLRP3 ATPase activity by cysteine modification, blocks NLRP3 inflammasome activation<\/span><\/td>\n(53<\/a>)<\/td>\n<\/tr>\n
CY-09<\/span><\/td>\nNLRP3<\/span><\/td>\nInhibits NLRP3 ATPase activity, blocks NLRP3 inflammasome activation<\/span><\/td>\n(69<\/a>)<\/td>\n<\/tr>\n
Tranilast<\/span><\/td>\nNLRP3<\/span><\/td>\nBinds to NLRP3 NACHT domain to block NLRP3-NLRP3 and NLRP3-ASC interaction<\/span><\/td>\n(52<\/a>)<\/td>\n<\/tr>\n
OLT1177<\/span><\/td>\nNLRP3<\/span><\/td>\nInhibits NLRP3 ATPase activity, blocks NLRP3 inflammasome activation<\/span><\/td>\n(70<\/a>)<\/td>\n<\/tr>\n
Oridonin<\/span><\/td>\nNLRP3<\/span><\/td>\nBinds to cysteine 279 of NLRP3 to abolish NLRP3-NEK7 interaction, blocks NLRP3 inflammasome activation<\/span><\/td>\n(71<\/a>)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.3″ custom_padding=”0|0px|27px|0px|false|false”][et_pb_column type=”4_4″ _builder_version=”3.19.3″ parallax=”off” parallax_method=”on”][et_pb_text _builder_version=”3.19.3″]<\/p>\n

Indirect Inhibitors<\/span><\/h3>\n
\n

Glyburide
<\/strong><\/span>
Glyburide is a sulfonylurea drug <\/span>which is<\/g> widely used in the United States for the treatment of T2D (72<\/a>). It inhibits ATP-sensitive K+<\/sup> (KATP<\/sub>) channels in pancreatic \u03b2 cells (73<\/a>). One study conducted by Lamkanfi et al. showed that glyburide prevents PAMP-, DAMP-, and crystal-induced NLRP3 inflammasome activation in bone marrow-derived macrophages (BMDMs). Its inhibitory potential seems to be specific for NLRP3 <\/span>inflammasome,<\/g> since it did not prevent the IL-1\u03b2 release from activated NLRC4 or NLRP1 pathway (48<\/a>). When tested in response to stimuli <\/span>which work<\/g> independent<\/g> of the P2X7 receptor but require TLR4 signaling, glyburide effectively prevented the activation of caspase-1 and 1L-1\u03b2 secretion, suggesting that it works downstream of the P2X7 receptor (48<\/a>). It did not block the caspase-1 activation in S. typhimurium<\/g><\/em>-infected BMDMs which do not require NLRP3 for caspase-1 activation (74<\/a>), suggesting that it works upstream of NLRP3 (48<\/a>). Furthermore, glyburide showed inhibitory activity in vitro<\/em> (48<\/a>, 75<\/a>) or in vivo<\/em> (76<\/a>) during NLRP3 inflammasome activation. However, the in vivo<\/em> doses of glyburide to exert its inhibitory <\/span>affect<\/g> are quite high, which <\/span>cause<\/g> hypoglycemia, therefore its usage is limited to T2D only (21<\/a>).<\/span><\/p>\n<\/div>\n

\n

 <\/p>\n

16673-34-0<\/span><\/h4>\n

16673-34-0 is an intermediate substrate produced during glyburide synthesis, however, it lacks the <\/span>cyclohexylurea<\/g> moiety of glyburide which is involved in insulin release, therefore, it does not affect glucose metabolism. A study carried out by Marchetti et al. in J774A.1 murine macrophages and primary adult rat cardiomyocytes showed that 16673-34-0 inhibits NLRP3 inflammasome formation, but shows no effect on AIM2 or NLRC4 inflammasome. When tested in vivo<\/em>, it showed <\/span>positive<\/g> outcome<\/g> in mouse models of non-reperfused and reperfused acute myocardial infarction. 16673-34-0 was tested with multiple diverse stimuli of <\/span>NLRP3<\/g> inflammasome, independent of which stimuli <\/span>is<\/g> used, inhibitory effects of 16673-34-0 remained the same suggesting that it interferes with downstream events involved in either NLRP3 conformational changes secondary to activation or binding to ASC (55<\/a>, 56<\/a>). However, the exact mechanism of inhibition is not completely clear and additional studies are needed to fully determine its inhibitory potential.<\/span><\/p>\n<\/div>\n

\n

 <\/p>\n

JC124<\/span><\/h4>\n

Kuwar et al. recently developed a novel small molecule JC124, through structural optimization of glyburide. JC124 was rationally designed to remove the potential hypoglycemic effects of glyburide. They explored the potential of JC124 for traumatic brain injury (TBI) therapy and it was demonstrated to exert significant anti-inflammatory effect to protect the injured brain following TBI. JC124 treatment significantly reduced the expression of NLRP3, ASC, caspase-1, pro-IL-1\u03b2, TNF\u03b1, and inducible nitric oxide synthase (iNOS). This targeting of NLRP3 inflammasome activation and its downstream neuroinflammatory cascade is suggested to confer JC124 its protective effect for TBI (57<\/a>). It blocked ASC aggregation, caspase-1 activation, and IL-1\u03b2 secretion. JC124 showed protective effects in a mouse model of acute myocardial infarction (77<\/a>) and in transgenic AD models (77<\/a>, 78<\/a>). Further studies aiming at determining the efficacy of JC124 will render more information for its translational value.<\/p>\n

<\/span><\/p>\n<\/div>\n

\n

FC11A-2<\/span><\/h4>\n

Liu et al. investigated a synthetic small molecular compound, 1-ethyl-5-methyl-2-phenyl-1H-benzo[d]imidazole, which is also known as FC11A-2, for its inhibitory potential of NLRP3 inflammasome. FC11A-2 was examined in THP-1 cells and in <\/span>mouse<\/g> model of dextran sulfate sodium (DSS)-induced experimental colitis, and it showed highly effective outcomes by repressing IL-1\u03b2\/18 release. FC11A-2 hindered the proximity-induced autocleavage of procaspase-1, eventually resulting in <\/span>reduced<\/g> amount of activated caspase-1, by a pathway <\/span>which is<\/g> independent of activation of NF-\u03baB (58<\/a>).<\/span><\/p>\n<\/div>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.3″][et_pb_column type=”4_4″ _builder_version=”3.19.3″ parallax=”off” parallax_method=”on”][et_pb_text _builder_version=”3.19.3″]<\/p>\n

Inhibitors for the Constituents of NLRP3 Inflammasome<\/span><\/h3>\n
\n

Parthenolide<\/span><\/h4>\n

Parthenolide is a plant sesquiterpene lactone and has numerous anti-inflammatory properties, therefore, it is utilized in herbal medicines of various inflammatory diseases (79<\/a>). It inhibited caspase-1 activation in response to NLRP1, NLRC4, and NLRP3 stimulation by alkylating many cysteine residues of caspase-1. Parthenolide can also target <\/span>ATPase<\/g> activity of NLRP3 protein directly, probably through cysteine modification (59<\/a>). However, it had poor solubility and bioavailability, therefore now its <\/span>water soluble<\/g> analogs are being evaluated (80<\/a>, 81<\/a>).<\/p>\n

<\/span><\/p>\n<\/div>\n

\n

VX-740 and VX-765<\/span><\/h4>\n

VX-740 (Pralnacasan) and its analog VX-765 are peptidomimetic inhibitor of caspase-1. They are prodrugs <\/span>which are<\/g> metabolized by plasma esterases to their corresponding <\/span>aldo<\/g>-acids (63<\/a>, 82<\/a>). Both <\/span>compound<\/g> act by covalent modification of the catalytic cysteine residue in the active site of caspase-1, hence they block caspase-1 and resultant cleavage of pro-IL-1\u03b2\/18 (61<\/a>). VX-740 showed good results for the treatment of rheumatoid arthritis (RA) and osteoarthritis (OA) in mice models (62<\/a>). In phase I and II clinical trials in RA patients, it exhibited significant anti-inflammatory effects with good <\/span>pharmacokinetics<\/g> profile (83<\/a>, 84<\/a>). However, hepatic toxicity in animals after its long-term exposure led to discontinuation of further development (85<\/a>). VX-765 showed even higher potency for RA and also showed <\/span>reduction<\/g> in IL-1\u03b2\/18 in <\/span>mouse<\/g> model of dermatitis. It also had positive outcomes for <\/span>treatment<\/g> of epilepsy and psoriasis in mice and was announced to undergo clinical trial (63<\/a>, 86<\/a>). Some recent findings have reported that VX-765 helped in alleviating the cognitive impairment and severity of AD in mice (87<\/a>). It also lowered myocardial infarction and preserved ventricular function in mice (88<\/a>).<\/p>\n

<\/span><\/p>\n<\/div>\n

\n

Bay 11-7082<\/span><\/h4>\n

Bay 11-7082 is a phenyl vinyl sulfone, it inhibits <\/span>NF-\u03baB<\/g> pathway through blockade of <\/span>kinase<\/g> activity of IKK\u03b2. It inhibits its target proteins using alkylation of essential nucleophilic residues, for <\/span>example<\/g> cysteines. Studies with NG5 cells and mouse primary BMDMs showed that bay 11-7082 prevents the organization of ASC pyroptosome and NLRP3 inflammasome function through alkylation of cysteine residues of NLRP3 ATPase region. Importantly, it showed selective inhibition of NLRP3 inflammasome as compare to other inflammasomes (59<\/a>). Recently, vinyl sulfone derivatives were used as antiparasitic agents in dogs and mice (89<\/a>), these preclinical trials revealed that these compounds are well-tolerated, non-mutagenic <\/span>and<\/g> have suitable pharmacokinetic profiles. They also permeate <\/span>cell<\/g> membrane easily (59<\/a>). Bay 11-7082 and <\/span>other<\/g> vinyl sulfone\/sulfonate compounds <\/span>provides<\/g> an <\/span>applicable<\/g> framework for <\/span>the future<\/g> design.<\/p>\n

<\/span><\/p>\n<\/div>\n

\n

\u03b2-Hydroxybutyrate (BHB)<\/span><\/h4>\n

\u00df-<\/span>hydroxy butyrate<\/g> (BHB) is a ketone metabolite, which was tested by Youm et al. for <\/span>NLRP3<\/g> inflammasome blockade. It <\/span>affectively<\/g> lowered the production of IL-1\u00df and IL-18 in human monocytes in response to activated NLRP3 inflammasome, without interfering with activated AIM2 or NLRC4 inflammasome. Treatment of BMDMs from mouse models of <\/span>familial<\/g> cold <\/span>auto inflammatory<\/g> syndrome (FCAS) and <\/span>Muckle\u2013Wells<\/g> syndrome (MWS) with BHB dose-dependently inhibited constitutive NLRP3 inflammasome activation. BHB is effective only for canonical activation during which it inhibits K+<\/sup> efflux and reduces the oligomerization and speck formation of ASC. It blocks the activation of NLRP3 inflammasome independent of ROS, AMP-activated protein kinase, glycolytic inhibition, or autophagy (49<\/a>). From these <\/span>findings<\/g> it can be anticipated that pharmacological or dietary attempts to raise BHB level may reduce the severity of NLRP3-mediated chronic inflammatory diseases.<\/span><\/p>\n<\/div>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.3″ custom_padding=”0|0px|27px|0px|false|false”][et_pb_column type=”4_4″ _builder_version=”3.19.3″ parallax=”off” parallax_method=”on”][et_pb_text _builder_version=”3.19.3″]<\/p>\n

Direct Inhibitors of NLRP3 Protein<\/span><\/h3>\n
\n

MCC950<\/span><\/h4>\n

A <\/span>diarylsulfonylurea<\/g>-containing compound termed as MCC950, is considered one of the most potent and selective inhibitor of NLRP3 inflammasome. There is an extensive consideration in the development of MCC950 as a treatment for the NLRP3-driven disorders. MCC950 was previously reported to block the processing of IL-1\u03b2 by caspase-1 (54<\/a>), later it was described by Coll et al. that in mouse and human macrophages, MCC950 has the potential to block both canonical and non-canonical NLRP3 inflammasome activation and IL-1\u03b2 production by abrogating ASC oligomerization. Notably, MCC950 had no effect on AIM2, NLRC4, or NLRP1 inflammasome activation (67<\/a>, 90<\/a>, 91<\/a>). Another latest study has reported that MCC950 directly binds to the NLRP3 NACHT domain’s Walker B motif, and blocks the hydrolysis of ATP and formation of NLRP3 inflammasome (68<\/a>). Very recently, a preprint paper at BioRxiv has reported by utilizing photoaffinity labeling and iBody technology that MCC950 interacts with the NACHT domain of wild type NLRP3. The binding was lessened in most of CAPS-related NLRP3 mutants, moreover, in two mouse models of CAPS, MCC950 did not inhibit the NLRP3-driven inflammatory pathology. This study implies that MCC950 may only be effective in <\/span>inflammation driven<\/g> by wild type NLRP3 protein, but not in ailments driven by CAPS-related NLRP3 mutants (92<\/a>).<\/span><\/p>\n

MCC950 was reported to lower skin and pulmonary inflammation in mice (93<\/a>) and some other in vivo<\/g><\/em><\/span>experiments<\/g> in mouse<\/g> model of human MS showed that MCC950 alleviates the severity of EAE (67<\/a>). Oral treatment of MCC950 rescued the dopaminergic degeneration in a mouse model of Parkinson’s disease (PD) (94<\/a>). Future studies are needed to warrant the exact potential of MCC950.<\/span><\/p>\n<\/div>\n

\n

 <\/p>\n

3,4-Methylenedioxy-\u03b2-nitrostyrene (MNS)<\/span><\/h4>\n

A potent NLRP3 inhibitor, 3,4-Methylenedioxy-\u03b2-nitrostyrene (MNS) was found through screening a kinase inhibitory library by He et al. By utilizing immunoprecipitation, mass spectrometry, and mutational studies, it was demonstrated that MNS binds to the LRR and NACHT domains and suppresses ATPase activity of NLRP3, while the activation of AIM2 or NLRC4 inflammasomes was unaffected by it. MNS may directly target the cysteine(s) of NLRP3 as implicated by its inhibition of ATPase activity of NLRP3 (53<\/a>). Future studies on MNS may confer additional insights on this potential inhibitor.<\/span><\/p>\n<\/div>\n

\n

 <\/p>\n

CY-09<\/span><\/h4>\n

Jiang et al. identified an effective and direct inhibitor of NLRP3 which showed significant inhibition of NLRP3 inflammasome in vivo<\/em> in mice models and ex vivo<\/em> in human cells (52<\/a>). CY-09 is an analog of CFTR(<\/span>inh<\/g>)-172 (C172), which inhibits the cystic fibrosis transmembrane conductance regulator (CFTR) channel (95<\/a>). CY-09 lacks CFTR-inhibitory activity (96<\/a>). In BMDMs primed with LPS, CY-09 dose-dependently blocked the ATP, monosodium urate (MSU), and nigericin-induced activation of caspase-1 and resultant release of IL-1\u03b2. Its inhibitory effect is not dependent on signal 1 and NLRP3 post-translational modification (ubiquitination). Mechanistically, it directly interacts with the NLRP3 Walker A motif to eliminate the ATP binding of NLRP3, however, it does not affect NLRP1, NLRC4, RIG-1, or NOD2 (52<\/a>).<\/span><\/p>\n

CY-09 demonstrated outstanding preventive or therapeutic properties in the mice models of gout, T2D, and CAPS. Most importantly, it exhibited a promising pharmacokinetic profile and showed good oral bioavailability, safety, and stability. Nonetheless, more studies are required to broaden its full potential (52<\/a>).<\/span><\/p>\n<\/div>\n

\n

 <\/p>\n

Tranilast<\/span><\/h4>\n

Tranilast (N-[3\u2032,4\u2032-dimethoxycinnamoyl]-anthranilic acid, TR) is a tryptophan metabolite analog which showed<\/g> inhibitory potential for homologous passive cutaneous anaphylaxis (97<\/a>). TR is a fairly safe compound and its high doses showed appropriate tolerance levels when tested in patients (98<\/a>, 99<\/a>). It showed inhibitory<\/g> effect for NLRP3 inflammasome but not for NLRC4 or AIM2 inflammasome. TR impaired the endogenous NLRP3-ASC interaction but did not affect the NLRP3-NEK7 interaction, raising the possibility that it targets NLRP3 directly. Indeed, it was demonstrated to bind to the NLRP3 NACHT domain and, abolish the direct NLRP3-NLRP3 interaction (52<\/a>). Moreover, TR does not impede with the upstream signaling events of NLRP3 inflammasome, e.g., expression of NLRP3 and pro-IL-1\u03b2, ROS production, K+<\/sup> efflux, chloride efflux, and mitochondrial damage. TR has demonstrated significant therapeutic and preventive outcomes in gout, CAPS, and T2D mice models (69<\/a>). Considering the high safety of TR in clinic, it can be of significant importance for treating NLRP3-driven diseases.<\/span><\/p>\n<\/div>\n

\n

 <\/p>\n

OLT1177<\/span><\/h4>\n

OLT1177 is an active \u03b2-sulfonyl nitrile compound, which cleared phase I clinical trial for the treatment of degenerative arthritis successfully, and now being evaluated under phase II clinical trial (100<\/a>).<\/span><\/p>\n

A study in mice model of MSU- and zymosan-induced arthritis by Marchetti et al. demonstrated that OLT1177 has the potential to lower the neutrophil infiltration and joint swelling, as well as to inhibit the secretion of IL-1\u03b2 and IL-6. In in vitro<\/em> studies, OLT1177 blocked both canonical and non-canonical activation of NLRP3 inflammasome and showed direct binding with NLRP3 to block its ATPase activity. Moreover, in monocytes from CAPS patients, it lowered caspase-1 activity and resultant IL-1\u03b2 secretion,<\/g> and reduced LPS-induced systemic inflammation in mice. Significantly, OLT1177 did not inhibit NLRC4 or AIM2 inflammasome. OLT1177 was given orally to the healthy subjects in phase 1 trials, and it showed good safety and tolerance levels. Additionally, it had long<\/g> half-life and did not show any organ or hematological toxicity at various doses (70<\/a>). Thus, OLT1177 seems to have a significant potential to treat NLRP3-related diseases.<\/span><\/p>\n<\/div>\n

\n

 <\/p>\n

Oridonin<\/span><\/h4>\n

Oridonin (Ori) is a bioactive ent-<\/span>kaurane<\/g> diterpenoid, a main<\/g> component of herbal plant Rabdosia rubescens<\/g><\/em>, which is extensively utilized in traditional Chinese medicine (101<\/a>, 102<\/a>). There are a number of anticancer activities which have<\/g> been associated with Ori, such as cell cycle arrest, angiogenesis suppression and<\/g> apoptosis induction (103<\/a>, 104<\/a>). It is reported to inhibit the NF-\u03baB or MAPK activation and repress the release of inflammasome-independent proinflammatory cytokines release (105<\/a>\u2013107<\/a>). Furthermore, it has good therapeutic effects on neuroinflammation, sepsis and<\/g> colitis (108<\/a>\u2013110<\/a>). He et al. reported that Ori interacts with the cysteine 279 of NLRP3 NACHT domain through a covalent bond, abolishes NLRP3-NEK7 interaction,<\/g> and inhibits consequent activation of NLRP3 inflammasome. The inhibitory effects of Ori are limited to NLRP3 inflammasome only and it does not inhibit AIM2 or NLRC4 inflammasome activation. When used in mice models of T2D, peritonitis and<\/g> gouty arthritis, Ori exhibited significant preventive, and therapeutic effects (71<\/a>). Thus, it can be anticipated that future studies may establish Ori as a clinically applicable inhibitor of NLRP3 inflammasome.<\/span><\/p>\n<\/div>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.3″ custom_padding=”0|0px|27px|0px|false|false”][et_pb_column type=”4_4″ _builder_version=”3.19.3″ parallax=”off” parallax_method=”on”][et_pb_text _builder_version=”3.19.3″]<\/p>\n

Concluding Remarks<\/span><\/h2>\n

NLRP3-induced pyroptosis and IL-1\u03b2\/18 secretion <\/span>is<\/g> linked to various diseases. The extent to which NLRP3 inflammasome activation contributes to the pyroptosis is still unclear, however, NLRP3 activation does results in pyroptosis which in turn can cause serious injury to vital organs (111<\/a>). At present, to treat NLRP3-associated diseases, many drugs are available which block IL-1\u03b2 such as neutralizing IL-1\u03b2 antibody canakinumab, recombinant IL-1 receptor antagonist anakinra, and the soluble decoy IL-1 receptor rilonacept. These biological agents are being used to treat CAPS and other diseases associated with IL-1\u03b2 (112<\/a>). However, activated NLRP3 inflammasome does not produce only IL-1\u03b2, there are other cytokines such as IL-18 which may also contribute to the NLRP3-associated disorders (113<\/a>, 114<\/a>). Moreover, IL-1\u03b2 production can be mediated by other inflammasomes or by inflammasome-independent pathways; thus inhibitors aimed at IL-1\u03b2 can result in unintentional immunosuppressive effects. Therefore, pharmacological inhibitors <\/span>which specifically<\/g> target the NLRP3 inflammasome only could be a better option for <\/span>treatment<\/g> of NLRP3-associated diseases. NLRP3-induced pyroptosis has been reported by many recent studies as a critical mechanism contributing to the NLRP3 inflammasome related pathologies (115<\/a>, 116<\/a>). Emerging <\/span>evidences<\/g> have reported GSDMD as an executive protein responsible for pyroptosis (117<\/a>, 118<\/a>), making it an attractive therapeutic target for curing NLRP3-induced pyroptosis associated diseases. Future studies should take advantage of <\/span>now<\/g> available structure of NLRP3 and focus on the development of structure-guided direct inhibitors with improved specificity and potency. Furthermore, nanobodies (Nbs) are now being explored extensively as therapeutics due to their high specificity, stability, and low toxicity (119<\/a>, 120<\/a>). It can be anticipated that Nbs may also be evaluated for NLRP3 inflammasome inhibition. In the past decade, great leaps forward were made to determine the structure of NLRP3 inflammasome, its activation mechanisms <\/span>and<\/g> its contribution to the initiation and progression of different diseases. Moreover, many <\/span>small molecule<\/g> inhibitors for NLRP3 inflammasome have been reported and some of them have shown remarkable therapeutic potential. However, none of them is currently approved by food and drug administration (FDA) or other agents. Current research should focus on the development of specific, small-molecular inhibitors of NLRP3 inflammasome which have improved pharmacokinetic properties, can penetrate the <\/span>blood brain<\/g> barrier more readily <\/span>and<\/g> be more cost-effective.<\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.3″ custom_padding=”0|0px|27px|0px|false|false”][et_pb_column type=”4_4″ _builder_version=”3.19.3″ parallax=”off” parallax_method=”on”][et_pb_text _builder_version=”3.19.3″]<\/p>\n

Author Contributions<\/span><\/h2>\n

AZ prepared the draft. All authors revised the draft.<\/p>\n

<\/span><\/p>\n

\n

Conflict of Interest<\/span><\/h3>\n

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<\/span><\/p>\n<\/div>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.3″ custom_padding=”0|0px|27px|0px|false|false”][et_pb_column type=”4_4″ _builder_version=”3.19.3″ parallax=”off” parallax_method=”on”][et_pb_text _builder_version=”3.19.3″]<\/p>\n

Footnotes<\/span><\/h2>\n
\n

Funding.<\/strong>
TJ was supported by the Strategic Priority Research Program of the Chinese Academy of Sciences (Grant No. XDB29030104), the National Natural Science Fund (Grant No. 31870731 and U1732109), the Fundamental Research Funds for the Central Universities, and the 100 Talents Programme of the Chinese Academy of Sciences. AZ was supported by <\/span>CAS-TWAS<\/g> fellowship. AK was supported by <\/span>Chinese<\/g> Government Scholarship. JT was supported by the National Natural Science Foundation of China (81771774), the Anhui Provincial Natural Science Foundation (1708085MH191), and the Key Projects of Research and Development Program of Anhui Provence (201904a07020103).<\/span><\/p>\n<\/div>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.19.3″ custom_padding=”0|0px|27px|0px|false|false”][et_pb_column type=”4_4″ _builder_version=”3.19.3″ parallax=”off” parallax_method=”on”][et_pb_text _builder_version=”3.19.3″]<\/p>\n

\n

References<\/h2>\n
\n
1. Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TK, et al. . Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity<\/span>. Nature<\/span>. (2010) 464<\/span>:1367\u201370. 10.1038\/nature08900 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
2. Fullard N, O’Reilly S. Role of innate immune system in systemic sclerosis<\/span>. Semin Immunopathol.<\/span>(2015) 37<\/span>:511\u20137. 10.1007\/s00281-015-0503-7 [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
3. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-\u03b2<\/span>. Mol Cell.<\/span> (2002) 10<\/span>:417\u201326. 10.1016\/S1097-2765(02)00599-3 [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
4. Sanders M, Parsons M, Howard A, Liu J, Fassio S, Martinez J, et al. . Single-cell imaging of inflammatory caspase dimerization reveals differential recruitment to inflammasomes<\/span>. Cell Death Dis<\/span>. (2015) 6<\/span>:e1813. 10.1038\/cddis.2015.186 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
5. Schroder K, Tschopp J. The inflammasomes<\/span>. Cell.<\/span> (2010) 140<\/span>:821\u201332. 10.1016\/j.cell.2010.01.040 [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
6. Minkiewicz J, de Rivero Vaccari JP, Keane RW. Human astrocytes express a novel NLRP2 inflammasome<\/span>. Glia<\/span>. (2013) 61<\/span>:1113\u201321. 10.1002\/glia.22499 [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
7. Inoue M, Shinohara ML. The role of interferon-\u03b2 in the treatment of multiple sclerosis and experimental autoimmune encephalomyelitis\u2013in the perspective of inflammasomes<\/span>. Immunology<\/span>. (2013) 139<\/span>:11\u20138. 10.1111\/imm.12081 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
8. Ito M, Shichita T, Okada M, Komine R, Noguchi Y, Yoshimura A, et al. . Bruton’s tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury<\/span>. Nat Commun<\/span>. (2015) 6<\/span>:7360. 10.1038\/ncomms8360 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
9. Inoue M, Shinohara ML. Nlrp3 inflammasome and MS\/EAE<\/span>. Autoimmune Dis.<\/span> (2013) 2013<\/span>:859145. 10.1155\/2013\/859145 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
10. Zhong Y, Kinio A, Saleh M. Functions of NOD-like receptors in human diseases<\/span>. Front Immunol<\/span>. (2013) 4<\/span>:333. 10.3389\/fimmu.2013.00333 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
11. Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, et al. . The NALP3 inflammasome is involved in the innate immune response to amyloid-\u03b2<\/span>. Nat Immunol<\/span>. (2008) 9<\/span>:857\u201365. 10.1038\/ni.1636 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
12. Duncan JA, Bergstralh DT, Wang Y, Willingham SB, Ye Z, Zimmermann AG, et al. . Cryopyrin\/NALP3 binds ATP\/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signaling<\/span>. Proc Natl Acad Sci USA.<\/span> (2007) 104<\/span>:8041\u20136. 10.1073\/pnas.0611496104 [PMC free article<\/a>]<\/span>[PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
13. Sharif H, Wang L, Wang WL, Magupalli VG, Andreeva L, Qiao Q, et al. . Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome<\/span>. Nature<\/span>. (2019) 570<\/span>:338\u201343. 10.1038\/s41586-019-1295-z [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
14. Franchi L, Mu\u00f1oz-Planillo R, N\u00fa\u00f1ez G. Sensing and reacting to microbes through the inflammasomes<\/span>. Nat Immunol.<\/span> (2012) 13<\/span>:325\u201332. 10.1038\/ni.2231 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
15. Doyle SL, Campbell M, Ozaki E, Salomon RG, Mori A, Kenna PF, et al. . NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components<\/span>. Nat Med.<\/span>(2012) 18<\/span>:791\u20138. 10.1038\/nm.2717 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
16. Martinon F, P\u00e9trilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome<\/span>. Nature<\/span>. (2006) 440<\/span>:237\u201341. 10.1038\/nature04516 [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
17. Mariathasan S, Weiss DS, Newton K, McBride J, O’rourke K, Roose-Girma M, et al. . Cryopyrin activates the inflammasome in response to toxins and ATP<\/span>. Nature.<\/span> (2006) 440<\/span>:228\u201332. 10.1038\/nature04515 [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
18. Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, Sharp FA, et al. . Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1\u03b2 in type 2 diabetes<\/span>. Nat Immunol<\/span>. (2010) 11<\/span>:897\u2013904. 10.1038\/ni.1935 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
19. Mart\u00edn-S\u00e1nchez F, Diamond C, Zeitler M, Gomez A, Baroja-Mazo A, Bagnall J, et al. . Inflammasome-dependent IL-1\u03b2 release depends upon membrane permeabilisation<\/span>. Cell Death Different<\/span>. (2016) 23<\/span>:1219\u201331. 10.1038\/cdd.2015.176 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
20. Gaidt MM, Hornung V. The NLRP3 inflammasome renders cell death pro-inflammatory<\/span>. J Mol Biol<\/span>. (2018) 430<\/span>:133\u201341. 10.1016\/j.jmb.2017.11.013 [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
21. Mangan MS, Olhava EJ, Roush WR, Seidel HM, Glick GD, Latz E. Targeting the NLRP3 inflammasome in inflammatory diseases<\/span>. Nat Rev Drug Discov<\/span>. (2018) 17<\/span>:588\u2013606. 10.1038\/nrd.2018.97 [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
22. Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, Macdonald K, Speert D, et al. . Cutting edge: NF-\u03baB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression<\/span>. J Immunol<\/span>. (2009) 183<\/span>:787\u201391. 10.4049\/jimmunol.0901363 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
23. Franchi L, Eigenbrod T, Mu\u00f1ozplanillo R, Ozkurede U, Kim YG, Arindam C, et al. . Cytosolic double-stranded RNA activates the NLRP3 inflammasome via MAVS-induced membrane permeabilization and K+<\/sup>efflux<\/span>. J Immunol<\/span>. (2014) 193<\/span>:4214\u201322. 10.4049\/jimmunol.1400582 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
24. Juliana C, Fernandes-Alnemri T, Kang S, Farias A, Qin F, Alnemri ES. Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation<\/span>. J Biol Chem<\/span>. (2012) 287<\/span>:36617\u201322. 10.1074\/jbc.M112.407130 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
25. Ghonime MG, Shamaa OR, Das S, Eldomany RA, Fernandesalnemri T, Alnemri ES, et al. Inflammasome priming by LPS is dependent upon ERK signaling and proteasome function<\/span>. J Immunol<\/span>. (2014) 192<\/span>:3881\u20138. 10.4049\/jimmunol.1301974 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
26. Py BF, Kim MS, Vakifahmetoglunorberg H, Yuan J. Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity<\/span>. Mol Cell<\/span>. (2013) 49<\/span>:331\u20138. 10.1016\/j.molcel.2012.11.009 [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
27. Kim EH, Park MJ, Sun P, Lee ES. Increased expression of the NLRP3 inflammasome components in patients with Beh\u00e7et’s disease<\/span>. Journal of Inflammation. (2015) 12<\/span>:41. 10.1186\/s12950-015-0086-z [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
28. Ozaki E, Campbell M, Doyle SL. Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives<\/span>. J Inflamm Res<\/span>. (2015) 8<\/span>:15\u201327. 10.2147\/JIR.S51250 [PMC free article<\/a>]<\/span>[PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
29. Sutterwala FS, Haasken S, Cassel SL. Mechanism of NLRP3 inflammasome activation<\/span>. Ann NY Acad Sci<\/span>. (2014) 1319<\/span>:82\u201395. 10.1111\/nyas.12458 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
30. Heid ME, Keyel PA, Kamga C, Shiva S, Watkins SC, Salter RD. Mitochondrial reactive oxygen species induces NLRP3-dependent lysosomal damage and inflammasome activation<\/span>. J Immunol.<\/span> (2013) 191<\/span>:5230\u20138. 10.4049\/jimmunol.1301490 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
31. Gurung P, Lukens JR, Kanneganti T-D. Mitochondria: diversity in the regulation of the NLRP3 inflammasome<\/span>. Trends Mol Med<\/span>. (2015) 21<\/span>:193\u2013201. 10.1016\/j.molmed.2014.11.008 [PMC free article<\/a>]<\/span>[PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
32. Perregaux D, Gabel CA. Interleukin-1 beta maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity<\/span>. J Biol Chem.<\/span> (1994) 269<\/span>:15195\u2013203. [PubMed<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
33. P\u00e9trilli V, Papin S, Dostert C, Mayor A, Martinon F, Tschopp J. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration<\/span>. Cell Death Different<\/span>. (2007) 14<\/span>:1583\u20139. 10.1038\/sj.cdd.4402195 [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
34. Okada M, Matsuzawa A, Yoshimura A, Ichijo H. The lysosome rupture-activated TAK1-JNK pathway regulates NLRP3 inflammasome activation<\/span>. J Biol Chem<\/span>. (2014) 289<\/span>:32926\u201336. 10.1074\/jbc.M114.579961 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
35. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, et al. NLRP3 inflamasomes are required for atherogenesis and activated by cholesterol crystals that form early in disease<\/span>. Nature.<\/span>(2010) 464<\/span>:1357\u201361. 10.1038\/nature08938 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
36. Lee HM, Kim JJ, Kim HJ, Shong M, Ku BJ, Jo EK. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes<\/span>. Diabetes<\/span>. (2013) 62<\/span>:194\u2013204. 10.2337\/db12-0420 [PMC free article<\/a>]<\/span>[PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
37. Altaf A, Qu P, Zhao Y, Wang H, Lou D, Niu N. NLRP3 inflammasome in peripheral blood monocytes of acute coronary syndrome patients and its relationship with statins<\/span>. Coron Artery Dis<\/span>. (2015) 26<\/span>:409\u201321. 10.1097\/MCA.0000000000000255 [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
38. Patel MN, Bernard WG, Milev NB, Cawthorn WP, Figg N, Hart D, et al. . Hematopoietic IKBKE limits the chronicity of inflammasome priming and metaflammation<\/span>. Proc Natl Acad Sci USA<\/span>. (2015) 112<\/span>:506\u201311. 10.1073\/pnas.1414536112 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
39. Peng K, Liu L, Wei D, Lv Y, Wang G, Xiong W, et al. . P2X7R is involved in the progression of atherosclerosis by promoting NLRP3 inflammasome activation<\/span>. Int J Mol Med.<\/span> (2015) 35<\/span>:1179\u201388. 10.3892\/ijmm.2015.2129 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
40. Shao BZ, Wei W, Ke P, Xu ZQ, Zhou JX, Liu C. Activating cannabinoid receptor 2 alleviates pathogenesis of experimental autoimmune encephalomyelitis via activation of autophagy and inhibiting NLRP 3 inflammasome<\/span>. CNS Neurosci Ther<\/span>. (2014) 20<\/span>:1021\u20138. 10.1111\/cns.12349 [PMC free article<\/a>]<\/span>[PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
41. Inoue M, Williams KL, Gunn MD, Shinohara ML. NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis<\/span>. Proc Natl Acad Sci USA<\/span>. (2012) 109<\/span>:10480\u20135. 10.1073\/pnas.1201836109 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
42. Cheng YL, Song LQ, Huang YM, Xiong YW, Zhang XA, Sun H, et al. Effect of enterohaemorrhagic Escherichia coli<\/em> O 157: H 7-specific enterohaemolysin on interleukin-1\u03b2 production differs between human and mouse macrophages due to the different sensitivity of NLRP 3 activation<\/span>. Immunology<\/span>. (2015) 145<\/span>:258\u201367. 10.1111\/imm.12442 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
43. Guo W, Liu W, Jin B, Geng J, Li J, Ding H, et al. . Asiatic acid ameliorates dextran sulfate sodium-induced murine experimental colitis via suppressing mitochondria-mediated NLRP3 inflammasome activation<\/span>. Int Immunopharmacol<\/span>. (2015) 24<\/span>:232\u20138. 10.1016\/j.intimp.2014.12.009 [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
44. Sun Y, Zhao Y, Yao J, Zhao L, Wu Z, Wang Y, et al. . Wogonoside protects against dextran sulfate sodium-induced experimental colitis in mice by inhibiting NF-\u03baB and NLRP3 inflammasome activation<\/span>. Biochem pharmacol<\/span>. (2015) 94<\/span>:142\u201354. 10.1016\/j.bcp.2015.02.002 [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
45. Kolb R, Liu G-H, Janowski AM, Sutterwala FS, Zhang W. Inflammasomes in cancer: a double-edged sword<\/span>. Protein Cell.<\/span> (2014) 5<\/span>:12\u201320. 10.1007\/s13238-013-0001-4 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
46. Karki R, Man S, Kanneganti T. Inflammasomes and cancer<\/span>. Cancer Immunol Res<\/span>. 5<\/span>:94\u201399. 10.1158\/2326-6066.CIR-16-0269 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
47. Ozkurede V, Franchi L. Immunology in clinic review series; focus on autoinflammatory diseases: role of inflammasomes in autoinflammatory syndromes<\/span>. Clin Exp Immunol<\/span>. (2012) 167<\/span>:382\u201390. 10.1111\/j.1365-2249.2011.04535.x [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
48. Lamkanfi M, Mueller JL, Vitari AC, Misaghi S, Fedorova A, Deshayes K, et al. . Glyburide inhibits the Cryopyrin\/Nalp3 inflammasome<\/span>. J Cell Biol<\/span>. (2009) 187<\/span>:61\u201370. 10.1083\/jcb.200903124 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
49. Youm Y-H, Nguyen KY, Grant RW, Goldberg EL, Bodogai M, Kim D, et al. . The ketone metabolite \u03b2-hydroxybutyrate blocks NLRP3 inflammasome\u2013mediated inflammatory disease<\/span>. Nat Med.<\/span> (2015) 21<\/span>:263\u20139. 10.1038\/nm.3804 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
50. Hu Z, Murakami T, Suzuki K, Tamura H, Kuwahara-Arai K, Iba T, et al. . Antimicrobial cathelicidin peptide LL-37 inhibits the LPS\/ATP-induced pyroptosis of macrophages by dual mechanism<\/span>. PLoS ONE.<\/span>(2014) 9<\/span>:e85765. 10.1371\/journal.pone.0085765 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
51. Liu Y, Lian K, Zhang L, Wang R, Yi F, Gao C, et al. . TXNIP mediates NLRP3 inflammasome activation in cardiac microvascular endothelial cells as a novel mechanism in myocardial ischemia\/reperfusion injury<\/span>. Basic Res Cardiol<\/span>. (2014) 109<\/span>:415. 10.1007\/s00395-014-0415-z [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
52. Jiang H, He H, Chen Y, Huang W, Cheng J, Ye J, et al. . Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders<\/span>. J Exp Med<\/span>. (2017) 214<\/span>:3219\u201338. 10.1084\/jem.20171419 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
53. He Y, Varadarajan S, Mu\u00f1oz-Planillo R, Burberry A, Nakamura Y, N\u00fa\u00f1ez G. 3, 4-methylenedioxy-\u03b2-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome<\/span>. J Biol Chem<\/span>. (2014) 289<\/span>:1142\u201350. 10.1074\/jbc.M113.515080 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
54. Perregaux DG, McNiff P, Laliberte R, Hawryluk N, Peurano H, Stam E, et al. . Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors<\/span>. J Pharmacol Exp Ther<\/span>. (2001) 299<\/span>:187\u201397. [PubMed<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
55. Marchetti C, Toldo S, Chojnacki J, Mezzaroma E, Liu K, Salloum FN, et al. Pharmacologic inhibition of the NLRP3 inflammasome preserves cardiac function after ischemic and non-ischemic injury in the mouse<\/span>. J Cardiovasc Pharmacol<\/span>. (2015) 66<\/span>:1\u20138. 10.1097\/FJC.0000000000000247 [PMC free article<\/a>]<\/span>[PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
56. Marchetti C, Chojnacki J, Toldo S, Mezzaroma E, Tranchida N, Rose SW, et al. A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury following ischemia-reperfusion in the mouse<\/span>. J Cardiovasc Pharmacol<\/span>. (2014) 63<\/span>:316\u201322. 10.1097\/FJC.0000000000000053 [PMC free article<\/a>]<\/span>[PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
57. Kuwar R, Rolfe A, Di L, Xu H, He L, Jiang Y, et al. . A novel small molecular NLRP3 inflammasome inhibitor alleviates neuroinflammatory response following traumatic brain injury<\/span>. J Neuroinflamm.<\/span> (2019) 16<\/span>:81. 10.1186\/s12974-019-1471-y [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
58. Liu W, Guo W, Wu J, Luo Q, Tao F, Gu Y, et al. . A novel benzo[d]imidazole derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of NLRP3 inflammasome<\/span>. Biochem Pharmacol<\/span>. (2013) 85<\/span>:1504\u201312. 10.1016\/j.bcp.2013.03.008 [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
59. Juliana C, Fernandes-Alnemri T, Wu J, Datta P, Solorzano L, Yu J-W, et al. . Anti-inflammatory compounds parthenolide and Bay 11\u20137082 are direct inhibitors of the inflammasome<\/span>. J Biol Chem<\/span>. (2010) 285<\/span>:9792\u2013802. 10.1074\/jbc.M109.082305 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
60. Saadane A, Masters S, Didonato J, Li J, Berger M. Parthenolide inhibits I\u03baB Kinase, NF-\u03baB activation, and inflammatory response in cystic fibrosis cells and mice<\/span>. Am J Respir Cell Mol Biol<\/span>. (2007) 36<\/span>:728\u201336. 10.1165\/rcmb.2006-0323OC [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
61. Boxer MB, Shen M, Auld DS, Wells JA, Thomas CJ. A Small Molecule Inhibitor of Caspase 1<\/span>. Probe Reports from the NIH Molecular Libraries Program [Internet]<\/span>. Bethesda, MD: National Center for Biotechnology Information; (2010). [Google Scholar<\/a>]<\/span><\/span><\/div>\n
62. Rudolphi K, Gerwin N, Verzijl N, Kraan PVD, Berg WVD. Pralnacasan, an inhibitor of interleukin-1\u03b2 converting enzyme, reduces joint damage in two murine models of osteoarthritis<\/span>. Osteoarthritis Cartilage<\/span>. (2003) 11<\/span>:738\u201346. 10.1016\/S1063-4584(03)00153-5 [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
63. Wannamaker W, Davies R, Namchuk M, Pollard J, Ford P, Ku G, et al. (S)-1-((S)-2-{[1-(4-Amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an Orally Available Selective Interleukin (IL)-Converting Enzyme\/Caspase-1 Inhi<\/span>. J Pharmacol Exp Ther<\/span>. (2007) 321<\/span>:509\u201316. 10.1124\/jpet.106.111344 [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
64. Strickson S, Campbell DG, Emmerich CH, Knebel A, Plater L, Ritorto MS, et al. . The anti-inflammatory drug BAY 11\u20137082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system<\/span>. Biochem J<\/span>. (2013) 451<\/span>(Pt 3):427\u201337. 10.1042\/BJ20121651 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
65. Meng X, Martinez MA, Raymond-Stintz MA, Winter SS, Wilson BS. IKK inhibitor bay 11-7082 induces necroptotic cell death in precursor-B acute lymphoblastic leukaemic blasts<\/span>. Br J Haematol<\/span>. (2010) 148<\/span>:487\u201390. 10.1111\/j.1365-2141.2009.07988.x [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
66. Krishnan N, Bencze G, Cohen P, Tonks NK. The anti-inflammatory compound BAY 11\u20137082 is a potent inhibitor of Protein Tyrosine Phosphatases<\/span>. FEBS J<\/span>. (2013) 280<\/span>:2830\u201341. 10.1111\/febs.12283 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
67. Coll RC, Robertson AA, Chae JJ, Higgins SC, Mu\u00f1oz-Planillo R, Inserra MC, et al. . A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases<\/span>. Nat Med.<\/span> (2015) 21<\/span>:248\u201355. 10.1038\/nm.3806 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
68. Coll RC, Hill JR, Day CJ, Zamoshnikova A, Boucher D, Massey NL, et al. . MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition<\/span>. Nat Chem Biol<\/span>. (2019) 15<\/span>:556\u20139. 10.1038\/s41589-019-0277-7 [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
69. Huang Y, Jiang H, Chen Y, Wang X, Yang Y, Tao J, et al. . Tranilast directly targets NLRP3 to treat inflammasome-driven diseases<\/span>. EMBO Mol Med<\/span>. (2018) 10<\/span>:e8689. 10.15252\/emmm.201708689 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
70. Marchetti C, Swartzwelter B, Gamboni F, Neff CP, Richter K, Azam T, et al. . OLT1177, a \u03b2-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation<\/span>. Proc Natl Acad Sci USA<\/span>. (2018) 115<\/span>:E1530\u20139. 10.1073\/pnas.1716095115 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
71. He H, Jiang H, Chen Y, Ye J, Wang A, Wang C, et al. . Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity<\/span>. Nat Commun<\/span>. (2018) 9<\/span>:2550. 10.1038\/s41467-018-04947-6 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
72. Riddle MC. Editorial: sulfonylureas differ in effects on ischemic preconditioning\u2013is it time to retire glyburide?<\/span> J Clin Endocrinol Metab<\/span>. (2003) 88<\/span>:528\u201330. 10.1210\/jc.2002-021971 [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
73. Ashcroft FM. ATP-sensitive potassium channelopathies: focus on insulin secretion<\/span>. J Clin Invest<\/span>. (2005) 115<\/span>:2047\u201358. 10.1172\/JCI25495 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
74. Mariathasan S, Newton K, Monack DM, Vucic D, French DM, Lee WP, et al. . Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf<\/span>. Nature.<\/span> (2004) 430<\/span>:213\u20138. 10.1038\/nature02664 [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
75. Hamon Y, Luciani MF, Becq F, Verrier B, Rubartelli A, Chimini G. Interleukin-1beta secretion is impaired by inhibitors of the Atp binding cassette transporter, ABC1<\/span>. Blood<\/span>. (1997) 90<\/span>:2911\u20135. 10.1182\/blood.V90.8.2911 [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
76. Lottaz D, Beleznay Z, Bickel M. Inhibition of ATP-binding cassette transporter downregulates interleukin-1beta-mediated autocrine activation of human dermal fibroblasts<\/span>. J Invest Dermatol.<\/span> (2001) 117<\/span>:871\u20136. 10.1046\/j.0022-202x.2001.01451.x [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
77. Fulp J, He L, Toldo S, Jiang Y, Boice A, Guo C, et al. . Structural insights of benzenesulfonamide analogues as NLRP3 inflammasome inhibitors: design, synthesis, and biological characterization<\/span>. J Med Chem.<\/span> (2018) 61<\/span>:5412\u201323. 10.1021\/acs.jmedchem.8b00733 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
78. Yin J, Zhao F, Chojnacki JE, Fulp J, Klein WL, Zhang S, et al. . NLRP3 inflammasome inhibitor ameliorates amyloid pathology in a mouse model of Alzheimer’s disease<\/span>. Mol Neurobiol<\/span>. (2018) 55<\/span>:1977\u201387. 10.1007\/s12035-017-0467-9 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
79. Heinrich M, Robles M, West JE, Ortiz de Montellano BR, Rodriguez E. Ethnopharmacology of Mexican asteraceae (compositae)<\/span>. Ann Rev Pharmacol Toxicol<\/span>. (1998) 38<\/span>:539\u201365. 10.1146\/annurev.pharmtox.38.1.539 [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
80. Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC, et al. . An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells<\/span>. Blood.<\/span>(2007) 110<\/span>:4427\u201335. 10.1182\/blood-2007-05-090621 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
81. D’anneo A, Carlisi D, Lauricella M, Puleio R, Martinez R, Di Bella S, et al. . Parthenolide generates reactive oxygen species and autophagy in MDA-MB231 cells. A soluble parthenolide analogue inhibits tumour growth and metastasis in a xenograft model of breast cancer<\/span>. Cell Death Dis.<\/span> (2013) 4<\/span>:e891. 10.1038\/cddis.2013.415 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
82. Mackenzie SH, Schipper JL, Clark AC. The potential for caspases in drug discovery<\/span>. Curr Opin Drug Discov Devel<\/span>. (2010) 13<\/span>:568\u201376. 10.4049\/jimmunol.168.6.3024 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
83. Siegmund B, Zeitz M. Pralnacasan (vertex pharmaceuticals)<\/span>. IDrugs<\/span>. (2003) 6<\/span>:154\u20138. [PubMed<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
84. Strand V, Sokolove J. Randomized controlled trial design in rheumatoid arthritis: the past decade<\/span>. Arthritis Res Ther<\/span>. (2009) 11<\/span>:205. 10.1186\/ar2555 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
85. Fischer U, Schulzeosthoff K. Apoptosis-based therapies and drug targets<\/span>. Cell Death Different<\/span>. (2005) 12<\/span>(Suppl 1<\/span>):942\u201361. 10.1038\/sj.cdd.4401556 [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
86. Maroso M, Balosso S, Ravizza T, Liu J, Bianchi ME, Vezzani A. Interleukin-1 type 1 receptor\/Toll-like receptor signalling in epilepsy: the importance of IL-1beta and high-mobility group box 1<\/span>. J Int Med<\/span>. (2011) 270<\/span>:319\u201326. 10.1111\/j.1365-2796.2011.02431.x [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
87. Flores J, No\u00ebl A, Foveau B, Lynham J, Lecrux C, Leblanc AC. Caspase-1 inhibition alleviates cognitive impairment and neuropathology in an Alzheimer’s disease mouse model<\/span>. Nat Commun<\/span>. (2018) 9<\/span>:3916. 10.1038\/s41467-018-06449-x [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
88. Audia JP, Yang XM, Crockett ES, Housley N, Haq EU, O’Donnell K, et al. . Caspase-1 inhibition by VX-765 administered at reperfusion in P2Y12 receptor antagonist-treated rats provides long-term reduction in myocardial infarct size and preservation of ventricular function<\/span>. Basic Res Cardiol.<\/span> (2018) 113<\/span>:32. 10.1007\/s00395-018-0692-z [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
89. Kerr ID, Lee JH, Farady CJ, Marion R, Rickert M, Sajid M, et al. . Vinyl sulfones as antiparasitic agents and a structural basis for drug design<\/span>. J Biol Chem<\/span>. (2009) 284<\/span>:25697\u2013703. 10.1074\/jbc.M109.014340 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
90. Daniels MJ, Rivers-Auty J, Schilling T, Spencer NG, Watremez W, Fasolino V, et al. . Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer’s disease in rodent models<\/span>. Nat Commun<\/span>. (2016) 7<\/span>:12504. 10.1038\/ncomms12504 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
91. Dempsey C, Araiz AR, Bryson K, Finucane O, Larkin C, Mills E, et al. . Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-\u03b2 and cognitive function in APP\/PS1 mice<\/span>. Brain Behav Immun<\/span>. (2017) 61<\/span>:306\u201316. 10.1016\/j.bbi.2016.12.014 [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
92. Vande Walle L, Stowe IB, \u0160\u00e1cha P, Lee BL, Demon D, Fossoul A, et al. MCC950\/CRID3 potently targets the NACHT domain of wildtype NLRP3 but not disease-associated mutants for inflammasome inhibition<\/span>. bioRxiv<\/span>. (2019) 634493 10.1101\/634493 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
93. Primiano MJ, Lefker BA, Bowman MR, Bree AG, Hubeau C, Bonin PD, et al. . Efficacy and pharmacology of the NLRP3 inflammasome inhibitor CP-456,773 (CRID3) in murine models of dermal and pulmonary inflammation<\/span>. J Immunol<\/span>. (2016) 197<\/span>:2421\u201333. 10.4049\/jimmunol.1600035 [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
94. Gordon R, Albornoz EA, Christie DC, Langley MR, Kumar V, Mantovani S, et al. . Inflammasome inhibition prevents \u03b1-synuclein pathology and dopaminergic neurodegeneration in mice<\/span>. Sci Trans Med.<\/span>(2018) 10<\/span>:eaah4066. 10.1126\/scitranslmed.aah4066 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
95. Ma T, Thiagarajah JR, Yang H, Sonawane ND, Folli C, Galietta LJ, et al. . Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin\u2013induced intestinal fluid secretion<\/span>. J Clin Invest<\/span>. (2002) 110<\/span>:1651\u20138. 10.1172\/JCI16112 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
96. Sonawane N, Verkman A. Thiazolidinone CFTR inhibitors with improved water solubility identified by structure\u2013activity analysis<\/span>. Bioorgan Med Chem<\/span>. (2008) 16<\/span>:8187\u201395. 10.1016\/j.bmc.2008.07.044 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
97. Darakhshan S, Pour AB. Tranilast: a review of its therapeutic applications<\/span>. Pharmacol Res<\/span>. (2015) 91<\/span>:15\u201328. 10.1016\/j.phrs.2014.10.009 [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
98. Konneh M. Tranilast Kissei pharmaceutical<\/span>. IDrugs<\/span>. (1998) 1<\/span>:141\u20136. [PubMed<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
99. Platten M, Ho PP, Youssef S, Fontoura P, Garren H, Hur EM, et al. . Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite<\/span>. Science<\/span>. (2005) 310<\/span>:850\u20135. 10.1126\/science.1117634 [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
100. Toldo S, Abbate A. The NLRP3 inflammasome in acute myocardial infarction<\/span>. Nat Rev Cardiol<\/span>. (2018) 15<\/span>:203\u201314. 10.1038\/nrcardio.2017.161 [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
101. Kadota S, Basnet P, Ishii E, Tamura T, Namba T. Antibacterial activity of trichorabdal A from Rabdosia trichocarpa<\/em> against Helicobacter pylori<\/span>. Zentralblatt Bakteriol<\/span>. (1997) 286<\/span>:63\u20137. 10.1016\/S0934-8840(97)80076-X [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
102. Kuo L-M, Kuo C-Y, Lin C-Y, Hung M-F, Shen J-J, Hwang T-L. Intracellular glutathione depletion by oridonin leads to apoptosis in hepatic stellate cells<\/span>. Molecules<\/span>. (2014) 19<\/span>:3327\u201344. 10.3390\/molecules19033327 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
103. Ding Y, Ding C, Ye N, Liu Z, Wold EA, Chen H, et al. . Discovery and development of natural product oridonin-inspired anticancer agents<\/span>. Eur J Med Chem<\/span>. (2016) 122<\/span>:102\u201317. 10.1016\/j.ejmech.2016.06.015 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
104. Fujita E, Nagao Y, Kaneko K, Nakazawa S, Kuroda H. The antitumor and antibacterial activity of the Isodon diterpenoids<\/span>. Chem Pharm Bull<\/span>. (1976) 24<\/span>:2118\u201327. 10.1248\/cpb.24.2118 [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
105. Huang J, Wu L, Tashiro S-i, Onodera S, Ikejima T. A comparison of the signal pathways between the TNF\u03b1-and oridonin-induced Murine L929 fibrosarcoma cell death<\/span>. Acta Med Okayama<\/span>. (2005) 59<\/span>:261\u201370. 10.18926\/AMO\/31960 [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
106. Xu Y, Xue Y, Wang Y, Feng D, Lin S, Xu L. Multiple-modulation effects of Oridonin on the production of proinflammatory cytokines and neurotrophic factors in LPS-activated microglia<\/span>. Int Immunopharmacol<\/span>. (2009) 9<\/span>:360\u20135. 10.1016\/j.intimp.2009.01.002 [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
107. Zhao G, Zhang T, Ma X, Jiang K, Wu H, Qiu C, et al. . Oridonin attenuates the release of pro-inflammatory cytokines in lipopolysaccharide-induced RAW264. 7 cells and acute lung injury<\/span>. Oncotarget<\/span>. (2017) 8<\/span>:68153. 10.18632\/oncotarget.19249 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
108. Wang S, Zhang Y, Saas P, Wang H, Xu Y, Chen K, et al. Oridonin’s therapeutic effect: Suppressing T h1\/T h17 simultaneously in a mouse model of C rohn’s disease<\/span>. J Gastroenterol Hepatol<\/span>. (2015) 30<\/span>:504\u201312. 10.1111\/jgh.12710 [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
109. Wang S, Yang H, Yu L, Jin J, Qian L, Zhao H, et al. . Oridonin attenuates A\u03b21\u201342-induced neuroinflammation and inhibits NF-\u03baB pathway<\/span>. PLoS ONE<\/span>. (2014) 9<\/span>:e104745. 10.1371\/journal.pone.0104745 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
110. Zhang ZY, Daniels R, Schluesener HJ. Oridonin ameliorates neuropathological changes and behavioural deficits in a mouse model of cerebral amyloidosis<\/span>. J Cell Mol Med<\/span>. (2013) 17<\/span>:1566\u201376. 10.1111\/jcmm.12124 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
111. Jiang D, Chen S, Sun R, Zhang X, Wang D. The NLRP3 inflammasome: role in metabolic disorders and regulation by metabolic pathways<\/span>. Cancer Lett<\/span>. (2018) 419<\/span>:8\u201319. 10.1016\/j.canlet.2018.01.034 [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
112. Dinarello CA, van der Meer JW. Treating inflammation by blocking interleukin-1 in humans<\/span>. Semin Immunol.<\/span> (2013) 25<\/span>:469\u201384. 10.1016\/j.smim.2013.10.008 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
113. Nowarski R, Jackson R, Gagliani N, de Zoete MR, Palm NW, Bailis W, et al. . Epithelial IL-18 equilibrium controls barrier function in colitis<\/span>. Cell<\/span>. (2015) 163<\/span>:1444\u201356. 10.1016\/j.cell.2015.10.072 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
114. Lu B, Nakamura T, Inouye K, Li J, Tang Y, Lundb\u00e4ck P, et al. . Novel role of PKR in inflammasome activation and HMGB1 release<\/span>. Nature<\/span>. (2012) 488<\/span>:670\u20134. 10.1038\/nature11290 [PMC free article<\/a>]<\/span>[PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
115. Kanneganti A, Malireddi RS, Saavedra PH, Walle LV, Van Gorp H, Kambara H, et al. . GSDMD is critical for autoinflammatory pathology in a mouse model of Familial Mediterranean Fever<\/span>. Journal of Experimental Medicine. (2018) 215<\/span>:1519\u201329. 10.1084\/jem.20172060 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
116. Xiao J, Wang C, Yao J-C, Alippe Y, Xu C, Kress D, et al. . Gasdermin D mediates the pathogenesis of neonatal-onset multisystem inflammatory disease in mice<\/span>. PLoS Biol<\/span>. (2018) 16<\/span>:e3000047. 10.1371\/journal.pbio.3000047 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
117. Gaidt MM, Hornung V. Pore formation by GSDMD is the effector mechanism of pyroptosis<\/span>. EMBO J<\/span>. (2016) 35<\/span>:2167\u20139. 10.15252\/embj.201695415 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
118. Liu X, Zhang Z, Ruan J, Pan Y, Magupalli VG, Wu H, et al. . Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores<\/span>. Nature<\/span>. (2016) 535<\/span>:153\u20138. 10.1038\/nature18629 [PMC free article<\/a>]<\/span> [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
119. Salvador JP, Vilaplana L, Marco MP. Nanobody: outstanding features for diagnostic and therapeutic applications<\/span>. Anal Bioanal Chem<\/span>. (2019) 411<\/span>:1703\u201313. 10.1007\/s00216-019-01633-4 [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n
120. Konning D, Zielonka S, Grzeschik J, Empting M, Valldorf B, Krah S, et al. . Camelid and shark single domain antibodies: structural features and therapeutic potential<\/span>. Curr Opin Struct Biol<\/span>. (2017) 45<\/span>:10\u20136. 10.1016\/j.sbi.2016.10.019 [PubMed<\/a>] [CrossRef<\/a>] [Google Scholar<\/a>]<\/span><\/span><\/div>\n<\/div>\n<\/div>\n
\n
\n

Articles from Frontiers in Immunology<\/span> are provided here courtesy of Frontiers Media SA<\/strong><\/div>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

[et_pb_section fb_built=”1″ fullwidth=”on” _builder_version=”3.19.3″ background_image=”https:\/\/areyoucovidmune.com\/covidmune\/wp-content\/uploads\/2019\/11\/shutterstock_112250879.jpg” custom_padding=”0px|0px|0|0px|false|false”][et_pb_fullwidth_header title=”Are You CovidMune?™” text_orientation=”center” _builder_version=”3.19.3″ title_level=”h2″ title_font=”|800|||on|||#e02b20|” title_text_color=”#ffffff” content_font=”|700|||||||” content_text_color=”#000000″ subhead_font=”||||on|||#e02b20|” subhead_text_color=”#ffffff” subhead_font_size=”30px” background_image=”https:\/\/areyoucovidmune.com\/covidmune\/wp-content\/uploads\/2020\/04\/covid-19-dna.jpg” custom_button_one=”on” button_one_text_color=”#ffffff” button_one_border_color=”#e02b20″ button_one_font=”|600|||||||” box_shadow_style_button_one=”preset2″][\/et_pb_fullwidth_header][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.19.3″ custom_padding=”7px|0px|0|0px|false|false”][et_pb_row _builder_version=”3.19.3″ custom_padding=”27px|0px|0|0px|false|false”][et_pb_column type=”4_4″ _builder_version=”3.19.3″ parallax=”off” parallax_method=”on”][et_pb_text _builder_version=”3.19.3″] Pharmacological Inhibitors of the NLRP3 Inflammasome Front Immunol. 2019; 10: 2538. Published online 2019 Oct 25. doi:\u00a010.3389\/fimmu.2019.02538 PMCID: PMC6842943 PMID: […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":""},"_links":{"self":[{"href":"https:\/\/areyoucovidmune.com\/covidmune\/wp-json\/wp\/v2\/pages\/1171"}],"collection":[{"href":"https:\/\/areyoucovidmune.com\/covidmune\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/areyoucovidmune.com\/covidmune\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/areyoucovidmune.com\/covidmune\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/areyoucovidmune.com\/covidmune\/wp-json\/wp\/v2\/comments?post=1171"}],"version-history":[{"count":4,"href":"https:\/\/areyoucovidmune.com\/covidmune\/wp-json\/wp\/v2\/pages\/1171\/revisions"}],"predecessor-version":[{"id":1178,"href":"https:\/\/areyoucovidmune.com\/covidmune\/wp-json\/wp\/v2\/pages\/1171\/revisions\/1178"}],"wp:attachment":[{"href":"https:\/\/areyoucovidmune.com\/covidmune\/wp-json\/wp\/v2\/media?parent=1171"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}